Combination therapy with granulocyte colony-stimulating factor, all-trans retinoic acid, and low-dose cytotoxic drugs for acute myelogenous leukemia.
A 67-year-old man presented with acute myelogenous leukemia (M2). Peripheral blood examination revealed a leukocyte count of 1,700/mu l with 1% myeloblasts, and bone marrow aspiration showed 42.6% myeloblasts with Auer bodies. Culture of his marrow cells at diagnosis showed that granulocyte colony-stimulating factor (G-CSF) promoted cell proliferation, while all-trans retinoic acid (ATRA) inhibited the proliferative effect of G-CSF and induced differentiation. Combination therapy with G-CSF, ATRA, and low-dose cytotoxic drugs achieved complete remission without severe marrow suppression.
Usuki
K
K
Division of Hematology, Kanto Teishin Hospital, Tokyo.
Kitazume
K
K
Endo
M
M
Ito
K
K
Iki
S
S
Urabe
A
A
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003568:Cytidine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001088:Arabinonucleotides; D007166:Immunosuppressive Agents; D016179:Granulocyte Colony-Stimulating Factor; C061162:1-arabinofuranosylcytosine-5'-stearylphosphate; D014212:Tretinoin; D003520:Cyclophosphamide; D003568:Cytidine Monophosphate